Klinik
Çalışmalar
1. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 016;388(10057):2254-2263.
2. Haak T, Hanaire H, Ajjan R,Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for themanagement of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73.
3.Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019;42(7):1178-1184.
4. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809.
5. Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year ofnationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43(2):389-397.
6. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019.https://doi:10.1136/bmjdrc-2019-000809.
7. Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): aprospective observational real-world cohort study. Diabetes Care. 2020;43(2):389-397.
(p<0.0001)
Günde 11.7 saatten 16.8 saate5
(p<0.001)
T1 ve T2 hastalarda5
(p<0.001)
T2 hastalarda3
(p<0.001)
✓ Glukoz dalgalanmalarını daha iyi anladığını ve10
✓ Diyabetlerini yönetme konusunda kendilerini daha iyi hissettiklerini göstermiştir3,4
Diyet ve fiziksel aktivite gibi yaşam tarzı değişiklikleri yapan T2 diyabetliler, gelişmiş glukoz kontrolü elde etmektedir.8
(>10 mmol/L) 1 saat/gün, hipoglisemide geçirilen süre önemli bir artış olmadan (<70 mg/dL)9
Referanslar & Sorumluluk Reddi
Görseller sadece açıklama içindir. Gerçek hasta veya verisi değildir.
1. Dunn, T., et al. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. Diabetes Research and Clinical Practice; 137(2018) 37-46
2. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263.
3. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55–73.
4. Kröger J, et al. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther 2020;11(1):279–91.
5. Lang J, et al. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control [Poster 972]. Diabetes 2019 Jun; 68(Supplement 1). https://doi.org/10.2337/db19- 972-P.
6. Evans E, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1):83-95
7. Yaron M, et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care 2019;42(7):1178–84.
8. American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45 (Suppl. 1):S60–S82
9. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294–301.
10. Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019. https://doi:10.1136/bmjdrc-2019-000809
Ѱ. 4-12 yaş arası çocuklar için, en az 18 yaşında bir bakıcı FreeStyle Libre sistemini kullanmaları ve okumalarını yorumlamaları için onları denetlemekten, yönetmekten ve onlara yardımcı olmaktan sorumludur.
ADC-78955 v.1.0 08/23
The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.
Do you want to leave this page?
This is a product-specific website intended for HCPs of Turkey only. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence.